检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:康冬 尚进[1] 武峰 白婵 肖静[1] 赵占正[1] KANG Dong;SHANG Jin;WU Feng;BAI Chan;XIAO Jing;ZHAO Zhanzheng(Department of Nephrology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
机构地区:[1]郑州大学第一附属医院肾内科,郑州450052
出 处:《肾脏病与透析肾移植杂志》2020年第5期420-425,共6页Chinese Journal of Nephrology,Dialysis & Transplantation
基 金:国家自然科学基金(81873611);中原科技创新领军人才项目(194200510006)。
摘 要:目的:观察罗沙司他对初始透析患者肾性贫血的治疗效果。方法:回顾2019-05-29~2020-06-01于郑州大学第一附属医院收治的初始透析合并肾性贫血的患者52例,其中使用罗沙司他的患者作为观察组共24例,使用重组人促红细胞生成素(rhEPO)的患者作为对照组共28例,平均随访时间8周,分析两组患者临床资料、生化指标以及血红蛋白及铁代谢相关指标。结果:两组患者基线年龄、身高、体重、血红蛋白、铁代谢指标、脂代谢指标等无明显差异(P>0.05)。两组患者治疗8周后血红蛋白均较基线升高(P均<0.05),但血红蛋白变化值比较两组间无明显差异(观察组平均血红蛋白增加15.95±23.31 g/L,对照组为20.03±23.49 g/L)。观察组用药后较用药前血清铁降低,铁蛋白降低,总铁结合力升高,转铁蛋白饱和度降低,差异具有统计学意义(P均<0.05)。结论:初始透析的慢性肾脏病贫血患者应用罗沙司他治疗8周血红蛋白得到了有效升高,其疗效与重组人促红细胞生成素无显著差异。Objective:To observe therapeutic effect of roxadustat on renal anemia in patients with incident dialysis.Methodology:52 initial dialysis patients complicated with renal anemia were involved,who were treated in the First Affiliated Hospital of Zhengzhou University from May 29,2019 to June 1,2020.There were 24 patients in observation group who were treated with roxadustat,28 patients in control group who were treated with recombinant human erythropoietin(rhEPO).Clinical data and biochemical indexes before and after treatment were analyzed.Results:There were no significant differences in age,height,weight,hemoglobin,iron metabolism index,lipid metabolism index between two groups(P>0.05).After 8 weeks of treatment,the average hemoglobin increase level of roxadustat group was 15.95±23.31 g/L,and that of the control group was 20.03±23.49 g/L,and there was no significant difference between the two groups.Serum iron,ferritin and transferrin saturation in roxadustat group were decreased,and the total iron binding capacity was increased(P<0.05).Conclusion:Roxadustat is as effective as rhEPO in treatment of renal anemia in initial dialysis patients.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.7